Tatyana Simuni
Neurology · Chicago, ILNPI 1093748683
Payments from drug & device makers
Across 310 payments — averaging $11,200 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche TCRC, Inc.$1.4M
- Biogen$805K
- Eli Lilly$469K
- Sanofi$237K
- Amneal Pharmaceuticals LLC$144K
- UCB SA$100K
- plus $280K from 14 others
Across 23 payments — averaging $699.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$7K
- F. Hoffmann-la Roche AG$3K
- Sanofi$2K
- UCB, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- Biogen$54
What the payments were for
- Consulting fees$186,00581%
- Speaking & faculty fees$33,52215%
- Travel & lodging$7,9793%
- Food & beverage$1,9361%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche TCRC, Inc. | 78 | $1,436,494 |
| Biogen | 8 | $804,755 |
| Eli Lilly | 14 | $469,409 |
| Sanofi | 41 | $237,100 |
| Amneal Pharmaceuticals LLC | 33 | $144,194 |
| UCB SA | 10 | $100,438 |
| Sanofi US Services Inc. | 9 | $64,770 |
| F. Hoffmann-la Roche AG | 15 | $39,871 |
| Genentech, Inc. | 10 | $37,844 |
| Sunovion Pharmaceuticals Inc. | 20 | $29,891 |
| AbbVie(2 entities) | 3 | $22,115 |
| Acadia Pharmaceuticals Inc | 19 | $20,070 |
| GE HealthCare | 5 | $16,006 |
| Neurocrine Biosciences, Inc. | 6 | $14,173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $10,200 |
| MDD US Operations, LLC | 17 | $8,203 |
| Kyowa Kirin, Inc. | 7 | $5,759 |
| Tanabe Pharma America, Inc. | 3 | $4,287 |
| Sanofi-aventis U.S. LLC | 3 | $4,005 |
| Partner Therapeutics, Inc. | 1 | $2,500 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,472,082 in reported general payments places this provider in the 95th percentile of 790 neurology providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GocovriAmantadine Hcl | 13 | $74,958 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 110 | $3,946 |
| Propranolol Hcl ErPropranolol Hcl | 14 | $588 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 20 | $338 |
| Primidone | 11 | $221 |
| Fludrocortisone Acetate | 12 | $206 |
| Donepezil Hcl | 17 | $188 |
| Duloxetine Hcl | 13 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MDD US Operations, LLCGocovri | $8,203 | $74,95813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 neurology providers in Illinois.
Other neurology in Chicago
- Danny BegaChicago$2.8M
- Augusto MiravalleChicago$2.1M
- Leonard Verhagen MetmanChicago$1.8M
- Dusan StefoskiChicago$1.5M
- Kourosh RezaniaChicago$1.4M
- Adil JavedChicago$1.4M
- Deborah HallChicago$1.4M
- Thomas ShoemakerChicago$1.2M
- Neelum AggarwalChicago$944K
- Tao XieChicago$838K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.